Local Recurrence Rate Low With Radiation Boost in Breast Cancer Patients
By Elana Gotkine HealthDay Reporter
WEDNESDAY, March 27, 2024 -- For young breast cancer patients after complete excision, high- versus low-dose radiation yields slightly better local control but increased incidence of marked or moderate fibrosis in the boost area, according to a study presented at the annual European Breast Cancer Conference, held from March 20 to 22 in Milan.
Sophie Bosma, M.D., Ph.D., from The Netherlands Cancer Institute in Amsterdam, and colleagues presented the results of a 10-year primary analysis involving patients aged 50 years and younger with pT1-2, pN0-2a invasive breast cancer after complete excision. Participants were randomly assigned to receive a boost of 26 Gy or 16 Gy (high or low) to the tumor bed (1,211 and 1,210 patients, respectively). The primary end point was local control at 10 years, assuming significance as a 3.5 percent difference at 10 years.
The researchers found that overall, there were 109 local recurrences (61 and 48 with low and high boost, respectively). Local recurrence was the first event for 42 and 23 patients in the low- and high-boost arms, respectively. The 10-year local recurrence rate was 4.4 and 2.8 percent for patients treated with a low and high boost, respectively (hazard ratio, 0.61). Boost dose, final margin status, subtype, and chemotherapy use were factors significantly associated with local recurrence in a multivariable analysis. The cumulative incidence of marked or moderate fibrosis in the boost area was 27 and 48 percent for patients treated with low and high boost, respectively.
"In both groups local recurrence rates were very low and much better than expected," Bosma said in a statement. "Although we did find a difference between the two groups in terms of the recurrence rate, this was a small difference which must be weighed against the increase in side effects, such as fibrosis."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Omission of SLNB Feasible for Younger Patients With ER+/cN0 Breast Cancer
TUESDAY, May 28, 2024 -- A novel natural language understanding (NLU) pipeline can identify the rates of lymphedema and node positivity among women with estrogen receptor-positive...
Donepezil Not Beneficial for Cognitive Impairment in Breast Cancer Survivors
FRIDAY, May 24, 2024 -- A once-daily dose of donepezil does not improve cognitive function among breast cancer survivors exposed to chemotherapy one to five years earlier...
ASCO: Survivors of Early Breast Cancer Can Successfully Attempt Pregnancy
THURSDAY, May 23, 2024 -- Most survivors of stage 0 to III breast cancer who attempt pregnancy postdiagnosis are able to become pregnant and have a live birth, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.